CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||100 mg/5mL and 400 mg/20mL|
|Indication||Multiple Myeloma (newly diagnosed)|
|Funding Request||In combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are not suitable for autologous stem cell transplant|
|Pre Noc Submission||No|
|NOC Date||November 27, 2018|
|Submission Date||January 4, 2019|
|Submission Deemed Complete||January 18, 2019|
|Stakeholder Input Deadline ‡||January 18, 2019|
|Check-point meeting||March 25, 2019|
|pERC Meeting||June 20, 2019|
|Initial Recommendation Issued||July 5, 2019|
|Feedback Deadline ‡||July 19, 2019|
|pERC Reconsideration Meeting||August 15, 2019|
|Final Recommendation Issued||August 29, 2019|
|Notification to Implement Issued||September 16, 2019|
|Therapeutic Area||BMP for Multiple Myeloma (newly diagnosed)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.